Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.

Abstract: The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.

Abstract: Described herein are methods and compositions relating to engineered curli fibers, e.g. CsgA polypeptide. In some embodiments, the methods and compositions described herein relate to functionalized biofilms.

Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.

Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.

Abstract: The present invention provides for a carrier complex for administration of therapeutic agents. In one aspect, an isolated C. botulinum carrier complex is provided, where the carrier complex lacks a native neurotoxin subunit.

Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae that contain fusion proteins. The antigens may be used therapeutically or prophylactically.

Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

Abstract: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.

Abstract: The invention provides compositions and uses for treating or preventing obesity and related diseases in patients.

Abstract: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).

Abstract: [Problem] To provide: a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent; and a method for producing a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration and includes a substance of interest having dispersibility in a non-polar solvent. [Solution] A lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent.

Abstract: The present invention relates to methods for stable transfection of Babesia parasites, and for vaccines conferring immunity against parasitic arthropods.

Abstract: The invention relates to compounds, compositions and methods for biofilm disruption and prevention. In particular, the invention relates to pharmaceutical compositions for the disruption of biofilm and prevention of biofilm in patients. The invention also relates to anti-biofouling compositions for the disruption of biofilm and prevention of biofilm on surfaces. The invention also relates to the removal of biological material from surfaces. The compositions of the invention include microbial deoxyribonucleases.

Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.

Abstract: The present invention pertains to a vaccine for administration to the upper respiratory tract of a ruminant to protect said ruminant against pneumonia caused by Mannheimia haemolytica, the vaccine comprising in combination live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, wherein the vaccine is for administration to the upper respiratory tract of the ruminant via intranasal atomization of the vaccine.

Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).

Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

Abstract: The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is F. psychrophilum and/or infectious pancreatic necrosis virus (IPNV).

Abstract: The present invention provides an immunogenic composition of a lipopolysaccharide vaccine and a non-alum adjuvant. The immunogenic composition may be detoxified J5 core lipopolysaccharide of Escherichia coli non-covalently complexed with group B meningococcal outermembrane protein. Also provided are methods for preventing an infection caused by a Gram-negative bacteria in an individual via administering the immunogenic compositions to the individual.